EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Not All Bruton's Tyrosine Kinase Inhibitors are Created Equal: Pharmacologic Insights into the Efficacy, Resistance, and Safety of Covalent and Non-covalent BTK Inhibitors

Giorgio Minotti

Canadian Hematology Today · 20.05.2026 · 2-7

DOI: 10.58931/cht.2026.5s0282 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Canadian Hematology Today, online erschienen am 20.05.2026. Verfasst von Giorgio Minotti. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

As the therapeutic landscape for B-cell malignancies continues to evolve, understanding the pharmacologic nuances of BTK inhibition has become increasingly important. In this interview, Rohit Khanna, publisher of Canadian Hematology Today, speaks with Giorgio Minotti, Professor of Pharmacology at the Università Campus Bio-Medico in Rome about the mechanistic differences between covalent and noncovalent BTK inhibitors, and the clinical implications for BTK inhibitor efficacy, resistance, and safety.

Zitieren

APA

Minotti, G. (2026). Not All Bruton's Tyrosine Kinase Inhibitors are Created Equal: Pharmacologic Insights into the Efficacy, Resistance, and Safety of Covalent and Non-covalent BTK Inhibitors. Canadian Hematology Today, 2-7. https://doi.org/10.58931/cht.2026.5s0282

Vancouver

Minotti G. Not All Bruton's Tyrosine Kinase Inhibitors are Created Equal: Pharmacologic Insights into the Efficacy, Resistance, and Safety of Covalent and Non-covalent BTK Inhibitors. Canadian Hematology Today. 2026:2-7. doi:10.58931/cht.2026.5s0282

BibTeX
@article{Minotti2026,
  author = {Minotti, Giorgio},
  title = {Not All Bruton's Tyrosine Kinase Inhibitors are Created Equal: Pharmacologic Insights into the Efficacy, Resistance, and Safety of Covalent and Non-covalent BTK Inhibitors},
  journal = {Canadian Hematology Today},
  year = {2026},
  pages = {2--7},
  doi = {10.58931/cht.2026.5s0282}
}
Kostenlos starten →